Biosimilars offer high-quality, lower-cost cancer treatments. Learn how they’re helping patients and reshaping global ...

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

Biocon's share price saw an uptick following key regulatory approvals in India for its Liraglutide drug, which is used in the ...

Prescription drugs prices have rapidly increased, but opting for generic medications and incorporating lifestyle changes are some ways to cut costs.

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone ...

The Food and Drug Administration (FDA) has approved Starjemza ® (ustekinumab-hmny), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Starjemza, ...

Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...

President Donald Trump put the biopharma industry on its back foot earlier this month with his executive order on ...

From five years of sales declines to nine consecutive quarters of growth, it’s hard to deny that Teva’s revamp under CEO Richard Francis is paying off. | By 2030, Teva now expects to achieve at least ...

Drugmakers will be expected to commit to aligning U.S. prices with the lowest price set in a group of peer nations for all ...